Conclusions: 200mcg/day of FP was as effective as 1000mcg/day in improving symptom control, airway inflammation, lung function and AHR in adults with mild to moderate asthma in the short term. Future studies should examine potential differential effects between low and high dose combination therapy (ICS/long acting beta agonist) on inflammation and airway remodeling over longer treatment periods.